These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34616012)

  • 1. Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
    Konukiewitz B; Schmitt M; Silva M; Pohl J; Lang C; Steiger K; Halfter K; Engel J; Schlitter AM; Boxberg M; Pfarr N; Wilhelm D; Foersch S; Tschurtschenthaler M; Weichert W; Jesinghaus M
    Br J Cancer; 2021 Dec; 125(12):1632-1646. PubMed ID: 34616012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple classifiers for molecular subtypes of colorectal cancer.
    Kim WG; Kim JY; Park DY
    Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
    Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
    Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
    Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
    Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.
    Schmitt M; Silva M; Konukiewitz B; Lang C; Steiger K; Halfter K; Engel J; Jank P; Pfarr N; Wilhelm D; Foersch S; Denkert C; Tschurtschenthaler M; Weichert W; Jesinghaus M
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphology Matters: A Critical Reappraisal of the Clinical Relevance of Morphologic Criteria From the 2019 WHO Classification in a Large Colorectal Cancer Cohort Comprising 1004 Cases.
    Jesinghaus M; Schmitt M; Lang C; Reiser M; Scheiter A; Konukiewitz B; Steiger K; Silva M; Tschurtschenthaler M; Lange S; Foersch S; Becker KF; Saur D; Friess H; Halfter K; Engel J; Boxberg M; Pfarr N; Wilhelm D; Weichert W
    Am J Surg Pathol; 2021 Jul; 45(7):969-978. PubMed ID: 34105518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.
    Kim JH; Kang GH
    World J Gastroenterol; 2014 Apr; 20(15):4230-43. PubMed ID: 24764661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
    Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
    Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
    BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Pathologic Analysis of Digitized Images of Colorectal Carcinoma Improves Prediction of Recurrence-Free Survival.
    Pai RK; Banerjee I; Shivji S; Jain S; Hartman D; Buchanan DD; Jenkins MA; Schaeffer DF; Rosty C; Como J; Phipps AI; Newcomb PA; Burnett-Hartman AN; Le Marchand L; Samadder NJ; Patel B; Swallow C; Lindor NM; Gallinger SJ; Grant RC; Westerling-Bui T; Conner J; Cyr DP; Kirsch R; Pai RK
    Gastroenterology; 2022 Dec; 163(6):1531-1546.e8. PubMed ID: 35985511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.